C9orf106

Across TCGA pan-cancer cohorts, C9orf106 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated C9orf106 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher C9orf106 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C9orf106 expression acts as an unfavorable survival marker.

BLCA and PAAD are the cancer types where C9orf106 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.117	0.720	<.001	36	view →
PAAD	DFS	Median	All	0.060	0.484	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

C9orf106–BLCA (OS)

Open the BLCA breakdown →